Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 688


Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.

Dirks M, Haag K, Pflugrad H, Tryc AB, Schuppner R, Wedemeyer H, Potthoff A, Tillmann HL, Sandorski K, Worthmann H, Ding X, Weissenborn K.

J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979. [Epub ahead of print]


High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.

El-Nahaas SM, Fouad R, Elsharkawy A, Khairy M, Elhossary W, Anwar I, Abdellatif Z, Maher RM, Bekheet N, Esmat G.

Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228. [Epub ahead of print]


Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.

Nehra V, Rizza SA, Temesgen Z.

Drugs Today (Barc). 2018 Jul;54(7):407-421. doi: 10.1358/dot.2018.54.7.2828188.


A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.

Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW.

PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018.


Hypersensitivity Reactions, Immediate.

Justiz Vaillant AA, Zito PM.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jul 16.



Freeman AM, Matto P.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jun 29.


Real life Egyptian experience of Daclatasvir plus Sofosbuvir with Ribavirin in naïve difficult to treat HCV patients.

Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M.

Infect Disord Drug Targets. 2018 Jul 16. doi: 10.2174/1871526518666180716141806. [Epub ahead of print]


Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C.

Evon DM, Golin CE, Ruffin R, Ayres S, Fried MW.

Pilot Feasibility Stud. 2018 Jun 27;4:92. doi: 10.1186/s40814-018-0285-5. eCollection 2018.


A case report of myocarditis combined with hepatitis caused by herpes simplex virus.

Yamamoto T, Kenzaka T, Matsumoto M, Nishio R, Kawasaki S, Akita H.

BMC Cardiovasc Disord. 2018 Jul 3;18(1):134. doi: 10.1186/s12872-018-0869-2.


Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/HIV Coinfection in a Community Care Setting.

Vijay G, Rajib HM, Mazin K, Sandipan C, Osama M, Sumit D, Amrendra Kumar M, Arshpal G, Pavani G, Ramakrishnaiah S, Khalid M, Jagannath S, Mohammed M, Smruti M.

Gut Liver. 2018 Jun 22. doi: 10.5009/gnl18004. [Epub ahead of print]


Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ.

Hepatol Int. 2018 Jun 21. doi: 10.1007/s12072-018-9879-5. [Epub ahead of print] Review.


Acute hepatitis E superinfection leading to chronic hepatitis B reactivation.

Aslam A, Susheela A, Iriana S, Chan SS, Lau D.

BMJ Case Rep. 2018 Jun 10;2018. pii: bcr-2017-223616. doi: 10.1136/bcr-2017-223616.


Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.

Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP.

Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.


Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications.

Kaliyaperumal K, Grove JI, Delahay RM, Griffiths WJH, Duckworth A, Aithal GP.

J Hepatol. 2018 May 21. pii: S0168-8278(18)32059-2. doi: 10.1016/j.jhep.2018.05.013. [Epub ahead of print] Review.


Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.

Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG.

Korean J Intern Med. 2018 May 25. doi: 10.3904/kjim.2017.368. [Epub ahead of print]


Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M.

Hepatol Int. 2018 May 12. doi: 10.1007/s12072-018-9868-8. [Epub ahead of print]


Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C.

de Medeiros LPJ, Lima MBC, Pires MMA, Maciel AMA, Medeiros RBV, Donadel MD, Pereira IMB, Leão FM, Pires LEACL, Rzetelna H, Brandão-Mello CE.

Osong Public Health Res Perspect. 2018 Apr;9(2):50-58. doi: 10.24171/j.phrp.2018.9.2.03.


Acute Gastritis and Splenic Infarction Caused by Epstein-Barr Virus.

Jeong JE, Kim KM, Jung HL, Shim JW, Kim DS, Shim JY, Park MS, Park SK.

Pediatr Gastroenterol Hepatol Nutr. 2018 Apr;21(2):147-153. doi: 10.5223/pghn.2018.21.2.147. Epub 2018 Apr 13.


Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Gao Y, Kraft JC, Yu D, Ho RJY.

Eur J Pharm Biopharm. 2018 Apr 17. pii: S0939-6411(18)30157-7. doi: 10.1016/j.ejpb.2018.04.014. [Epub ahead of print] Review.


Acute hepatitis E in a renal transplantation recipient: a case report.

Shindo M, Takemae H, Kubo T, Soeno M, Ando T, Morishita Y.

Int Med Case Rep J. 2018 Apr 5;11:77-80. doi: 10.2147/IMCRJ.S163865. eCollection 2018.

Supplemental Content

Loading ...
Support Center